A multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Catridecacog (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014, as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.